Shopping Cart
- Remove All
- Your shopping cart is currently empty
ATR-IN-23 (Compound 34), a potent and selective ATR inhibitor, exhibits an IC50 of 1.5 nM, has demonstrated antiproliferative effects on LoVo cells, and induces synthetic lethality in HT-29 cells, suggesting its utility in researching DNA damage response (DDR)-deficient cancers [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 6-8 weeks | |
50 mg | $1,980 | 6-8 weeks | |
100 mg | $2,500 | 6-8 weeks |
Description | ATR-IN-23 (Compound 34), a potent and selective ATR inhibitor, exhibits an IC50 of 1.5 nM, has demonstrated antiproliferative effects on LoVo cells, and induces synthetic lethality in HT-29 cells, suggesting its utility in researching DNA damage response (DDR)-deficient cancers [1]. |
In vitro | ATR-IN-23 exhibits significant inhibition of ATR with an IC50 value of 1.5 nM and demonstrates potent antiproliferative activity against LoVo cells, with an IC50 of 0.073 μM [1]. In HT-29 cells, ATR-IN-23 shows moderate antiproliferative efficacy with an IC50 of 0.161 μM [1]. |
In vivo | ATR-IN-23 exhibits acute toxicity at a maximum concentration of 2000 mg/kg, demonstrating moderate safety in ICR mice [1]. When administered at 50 mg/kg either once or twice daily via oral route for 21 days, ATR-IN-23 shows moderate antitumor efficacy in BALB/c nude mice [1]. |
Molecular Weight | 458.56 |
Formula | C20H22N6O3S2 |
Cas No. | 2923800-62-6 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.